ANNA SHUCK: Open Payments
NPI 1346885670 · LANSING, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$570 in 28 payments from 14 companies in 2025. Trend: 2023 $861 · 2024 $650 · 2025 $570
Food & beverage: $570
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 5 | $112 |
| ABBVIE INC. | 5 | $86 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $60 |
| Eisai Inc. | 2 | $51 |
| Novo Nordisk Inc | 2 | $47 |
| Lilly USA, LLC | 2 | $45 |
| GlaxoSmithKline, LLC. | 1 | $30 |
| PFIZER INC. | 2 | $28 |
| Teva Pharmaceuticals USA, Inc. | 1 | $27 |
| Aimmune Therapeutics, Inc. | 1 | $22 |
Products named: Veozah, CAPLYTA, UBRELVY, Leqembi, MOUNJARO, QULIPTA, TRELEGY ELLIPTA, AUSTEDO XR.
Industry payments across KS — which companies pay providers there.
